| Basics |
AnaptysBio, Inc.
AnaptysBio Inc is a biotechnology company. The company is engaged in developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. Its product include ANB020 and ANB019.
|
| IPO Date: |
January 26, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.23B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.95 | 2.66%
|
| Avg Daily Range (30 D): |
$1.08 | 2.96%
|
| Avg Daily Range (90 D): |
$0.89 | 3.13%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.31M |
| Avg Daily Volume (30 D): |
.5M |
| Avg Daily Volume (90 D): |
.45M |
| Trade Size |
| Avg Trade Size (Sh.): |
72 |
| Avg Trade Size (Sh.) (30 D): |
57 |
| Avg Trade Size (Sh.) (90 D): |
56 |
| Institutional Trades |
| Total Inst.Trades: |
3,065 |
| Avg Inst. Trade: |
$1.7M |
| Avg Inst. Trade (30 D): |
$2.34M |
| Avg Inst. Trade (90 D): |
$1.79M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.7M |
| Avg Closing Trade (30 D): |
$2.07M |
| Avg Closing Trade (90 D): |
$1.64M |
| Avg Closing Volume: |
53.12K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
|
$.54
|
$-1.34
|
|
Diluted EPS
|
|
$.52
|
$-1.34
|
|
Revenue
|
$
|
$ 76.32M
|
$ 22.26M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$
|
$ 15.11M
|
$ -38.63M
|
|
Operating Income / Loss
|
$
|
$ 34.7M
|
$ -26.17M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$
|
$ 65.54M
|
$ -54.34M
|
|
PE Ratio
|
|
|
|
|
|
|
